- Home
- LTBR vs ABUS Comparison
LTBR vs ABUS Comparison
Compare LTBR & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTBR
- ABUS
- Stock Information
- Founded
- LTBR 1992
- ABUS 2005
- Country
- LTBR United States
- ABUS United States
- Employees
- LTBR N/A
- ABUS N/A
- Industry
- LTBR Professional Services
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- LTBR Consumer Discretionary
- ABUS Health Care
- Exchange
- LTBR Nasdaq
- ABUS Nasdaq
- Market Cap
- LTBR 788.1M
- ABUS 711.2M
- IPO Year
- LTBR N/A
- ABUS N/A
- Fundamental
- Price
- LTBR $26.59
- ABUS $4.53
- Analyst Decision
- LTBR
- ABUS Strong Buy
- Analyst Count
- LTBR 0
- ABUS 2
- Target Price
- LTBR N/A
- ABUS $5.00
- AVG Volume (30 Days)
- LTBR 3.1M
- ABUS 961.2K
- Earning Date
- LTBR 10-29-2025
- ABUS 11-05-2025
- Dividend Yield
- LTBR N/A
- ABUS N/A
- EPS Growth
- LTBR N/A
- ABUS N/A
- EPS
- LTBR N/A
- ABUS N/A
- Revenue
- LTBR N/A
- ABUS $15,416,000.00
- Revenue This Year
- LTBR N/A
- ABUS $138.02
- Revenue Next Year
- LTBR N/A
- ABUS N/A
- P/E Ratio
- LTBR N/A
- ABUS N/A
- Revenue Growth
- LTBR N/A
- ABUS 53.23
- 52 Week Low
- LTBR $4.35
- ABUS $2.71
- 52 Week High
- LTBR $31.34
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- LTBR 63.34
- ABUS 57.70
- Support Level
- LTBR $23.12
- ABUS $4.10
- Resistance Level
- LTBR $31.34
- ABUS $4.65
- Average True Range (ATR)
- LTBR 2.83
- ABUS 0.22
- MACD
- LTBR 0.13
- ABUS -0.01
- Stochastic Oscillator
- LTBR 59.11
- ABUS 75.91
About LTBR Lightbridge Corporation
Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.